TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.~2. Must be 18 to 65 years old, inclusive, at the time of informed consent.~3. Must currently be self-administering Avonex Prefilled Syringes to treat MS and must have been self-administering Avonex Prefilled Syringes for the 12 weeks prior to the Screening Visit.~4. In the investigator's opinion, subjects must be willing and able to self-administer all injections required by the protocol.~5. Must speak English.~6. All male subjects and female subjects of child-bearing potential must practice effective contraception during the study.~Exclusion Criteria:~1. History of seizure disorder or unexplained blackouts OR history of a seizure within 3 months prior to the Screening Visit.~2. History of suicidal ideation within 3 months prior to Day 1 or an episode of severe depression within 3 months prior to Day 1. Severe depression is defined as any episode of depression that requires hospitalization, or the initiation of antidepressant therapy, or an increase in the dose of an existing regimen of antidepressant therapy. NOTE: Subjects receiving ongoing antidepressant therapy are not excluded from the study unless the dose has been increased within the 3 months prior to the Screening Visit.~3. Clinically significant local infection (for example cellulitis, abscess) or systemic infection (pneumonia, septicemia), at the discretion of the Investigator.~4. Known history of Human Immunodeficiency Virus (HIV).~5. Known history of, or positive test result for hepatitis C virus (test for hepatitis C virus antibody \[HCV Ab\]) or Hepatitis B virus (test for Hepatitis B Surface Antigen \[HBsAg\] and/or Hepatitis B Core Antibody \[HBcAb\]).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Avonex Single-Use Autoinjector (Type: EXPERIMENTAL): Participants received open label weekly treatment with Avonex 30 mcg intramuscular (IM) injections, provided in Avonex prefilled syringes.~In the Main Study, injection #1: administration of Avonex prefilled syringe via manual IM injection on Day 1. Injections #2, #3, and #4: administration of Avonex prefilled syringe using the single-use autoinjector on Days 8, 15, and 22, respectively. In the Extension Study, participants were to continue treatment with the Avonex single-use autoinjector for up to an additional 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Female sex~2. At least 18 years old at MBC diagnosis~3. Diagnosis of MBC at any point in patient history~   1. ICD-9 (174.x, 175.x) or ICD-10 (C50.xx) diagnosis of BC~  2. Confirmation of metastatic disease~  3. At least 2 document clinical visits~  4. Evidence of stage IV or recurrent MBC with a metastatic diagnosis date on or after 2011, as confirmed by unstructured clinical documents~4. HR+/HER2-~   1. HR+: ER+ or PR+ test before or up to 60 days after MBC diagnosis~  2. HER2-: any HER2 negative test and the absence of a positive test (IHC positive 3+, FISH positive/amplified, Positive NOS) before or up to 60 days after MBC diagnosis~5. Palbociclib + AI or letrozole as first-line therapy for MBC during the period from February/2015 through August /31/2018 (or 3 months prior to study cut-off date) to allow for a possible minimum follow-up time of 90 days until the study cutoff date. AI was administered within (±) 28 days of Palbociclib index date.~Exclusion Criteria:~1. Evidence of prior treatment with other CDK4/6I (Ribociclib or Abemaciclib), AI (Letrozole, Exemestane, and Anastrazole), Tamoxifen, Raloxifene, Toremifene, or Fulvestrant for MBC~2. First structured activity greater than 90 days after MBC diagnostic date~3. Treatment with a CDK4/6 inhibitor as part of a clinical trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palbociclib + an aromatase inhibitor (Type: None): Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
- Palbociclib + Letrozole (Type: None): Adult metastatic breast cancer patients who initiated Palbociclib +Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
- Letrozole (Type: None): Adult metastatic breast cancer patients who initiated Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* Infection with HCV genotype 1~* HCV RNA \> LLOQ at screening~* Participation in a prior Gilead-sponsored study~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~* Must be of generally good health, with the exception of chronic HCV infection, as determined by the Investigator~* Must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments~Key Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Co-infection with HIV or hepatitis B virus (HBV)~* Current or prior history of clinical hepatic decompensation (Groups 1 and 2 only)~* Hepatocellular carcinoma (HCC)~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF+RBV 12 weeks (Group 1) (Type: EXPERIMENTAL): Participants who failed a prior SOF+RBV ± pegylated interferon (Peg-IFN) regimen will receive LDV/SOF FDC plus RBV for 12 weeks.
- LDV/SOF 24 weeks (Group 2) (Type: EXPERIMENTAL): Participants who failed a prior LDV/SOF ± RBV regimen will receive LDV/SOF FDC for 24 weeks.
- LDV/SOF+RBV 24 weeks (Group 3) (Type: EXPERIMENTAL): Participants with advanced compensated or decompensated cirrhosis who failed a prior SOF+RBV regimen will receive LDV/SOF FDC plus RBV for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \>18 years of age~* Creatinine clearance ≤40 mL/min~* Hemoglobin 110-120 g/L~* Serum ferritin \<100 µg/L or transferrin saturation \<20%~* Monthly treatment with ESA and oral iron for at least six months before enrolment~Exclusion Criteria:~* Other obvious cause of acute or chronic anemia than iron deficiency~* Expectation to require hemodialysis within the next six months~* Short life expectancy (\<1 year)~* Pregnancy~* Decompensated heart failure~* History of allergic reactions to iron preparations and/or anaphylaxis from any cause~* Requirement of blood transfusions~* Chronic decompensated mental disorder or dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intravenous ferric carboxymaltose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of cough for more than 8 weeks~* Normal chest radiograph~* Idiopathic or treatment resistant cough (idiopathic defined as a cough for which no objective evidence of an underlying trigger can be determined after investigation or a cough that is unresponsive to 8 weeks of targeted treatment for identified underlying triggers including reflux disease, asthma and post-nasal drip \[treatment-resistant\]).~Exclusion Criteria:~* Current smoker~* Individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history~* Treatment with an angiotensin-converting-enzyme inhibitor (ACE-inhibitor) as the potential cause of a participant's cough, or requiring treatment with an ACE-inhibitor during the study or within 4 weeks prior to Day 0~* Forced Expiratory Volume (FEV1)/Forced Vital Capacity (FVC) \<60%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Gefapixant 600 mg>Placebo (Type: EXPERIMENTAL): Gefapixant, 600 mg, twice daily (BID), taken orally for 2 weeks followed by a 2-week washout period and then placebo to gefapixant, BID, taken orally for 2 weeks.
- Placebo>Gefapixant 600 mg (Type: EXPERIMENTAL): Placebo to gefapixant BID, taken orally for 2 weeks followed by a 2-week washout period and then gefapixant, 600 mg, BID, taken orally for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female subjects between 18 and 70 years of age, inclusive~* Primary diagnosis of narcolepsy with cataplexy~* Willing and able to comply with the study requirements~Exclusion Criteria:~* Other clinically significant conditions potentially causing EDS~* Clinically significant psychiatric disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- AXS-12 (reboxetine) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is greater than 18 years of age.~* Patient is scheduled to receive his/her first~course of cisplatin chemotherapy for a solid tumor.~* Patient has a prognosis (life expectancy) greater than or equal to 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parent/guardian can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.~* Born after a gestation period of 36 to 42 weeks inclusive.~* Healthy subjects as established by medical history before entering into the study.~* Written informed consent obtained from the parent or guardian of the subject.~Exclusion Criteria:~* Use of any investigational or non-registered product within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs from birth until first primary vaccination dose..~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Major congenital defects or serious chronic illness.~* Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and/or Hib vaccination or disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.~* The following condition is temporary or self limiting and a subject may be vaccinated once the condition has resolved and no other exclusion criteria are met:~* Current febrile illness or axillary temperature of ≥ 37.5 ºC or other moderate to severe illness within 24 hours of study vaccine administration.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- Aboriginal infants group (Type: EXPERIMENTAL): None
- Other Non-Aboriginal infants (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males \< 12 years of age~* Subjects with severe hemophilia A~* Previously treated with FVIII for \> 50 exposure days~Exclusion Criteria:~* Subjects with current evidence of or history of inhibitors to FVIII~* Any other inherited or acquired bleeding disorder~* Platelet counts \< 100,000/mm\^3~* Creatinine \> 2x the upper limit of normal~* Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) \> 5x the upper limit of normal

- Gender: MALE
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Main study (Type: EXPERIMENTAL): Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25-60 international units/kilogram (IU/kg) twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an intravenous (IV) infusion as per clinical needs of each subject up to at least 50 exposure days (EDs) and a minimum of at least 6 months.
- Part 2 (Expansion group) (Type: EXPERIMENTAL): Participants were administered with BAY94-9027 at a dose of 25-60 IU/kg twice per week for prophylaxis for 12 weeks.
- Extension study (Type: EXPERIMENTAL): Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25- 60 IU/kg twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an IV infusion as per clinical needs of each subject for at least 50 EDs or until marketing authorization of the drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of IVM/ALB Co-administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent signed by either the participant him/herself (≥21 years of age) or by parents and/or caregivers for children/adolescents; and written assent by child/adolescent (aged 6-20 years).~2. Agree to comply with study procedures, including provision of two stool samples at the beginning (baseline) and on three follow-up assessments (approximately 3 weeks, 6 months, and 12 months later).~3. Aged ≥6 to \<= 60 years for parallel group trial and ≥6 to \<=12 years for DF study.~4. At least two slides of the quadruple Kato-Katz thick smears positive for T. trichiura and infection intensities of at least 100 EPG.~Exclusion Criteria:~1. No written informed consent by individual/parents and/or caregiver.~2. Presence of major systemic illnesses, e.g. severe anemia (below 80 g/l Hb according to WHO \[28\]), clinical malaria as assessed by a medical doctor (positive Plasmodium RDT and ≥38 °C ear temperature), upon initial clinical assessment.~3. History of acute or severe chronic disease (e.g. cancer, diabetes, chronic heart, liver or renal disease).~4. Recent use of anthelmintic drug (within past 4 weeks).~5. Attending other clinical trials during the study.~6. Negative or low egg count (less than 100 EPG or less than 2 out of 4 slides positive) diagnostic result for T. trichiura eggs in the stool.~7. Known allergy to study medications (i.e. albendazole and ivermectin).~8. Pregnancy or lactating in the 1st week after birth (according to WHO guidelines within LF control programs \[29\]).~9. Currently taking medication with known interaction (e.g. for albendazole: cimetidine, praziquantel and dexamethasone; for ivermectin: warfarin).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: albendazole (Type: PLACEBO_COMPARATOR): 400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of placebo at day 0 administered orally
- Arm B: albendazole and ivermectin (Type: EXPERIMENTAL): 400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of ivermectin (Stromectol®) at day 0 administered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Positive for anti-HCV Ab (Antibody) and HCV RNA \>1,000 IU/mL at Screening.~2. Screening laboratory result indicating HCV genotype 1 infection.~3. Subject has never received antiviral treatment for hepatitis C infection (treatment-naive subject) or subject has received previous treatment with peginterferon with or without RBV with non-response (HCV RNA quantifiable at end of treatment or relapsed after end of treatment).~4. Estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73 m\^2 as estimated by the Modification of Diet in Renal Disease (MDRD) method.~Exclusion Criteria:~1. Women who are pregnant or breastfeeding.~2. Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency Virus (HIV Ab).~3. Any current or past clinical evidence of Child-Pugh B or C classification or clinical history of liver decompensation such as ascites (noted on physical exam), variceal bleeding, or hepatic encephalopathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 3-DAA (Direct Acting Antivirals) with or without RBV (Type: EXPERIMENTAL): 3-DAA (ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily \[QD\] and dasabuvir 250 mg twice daily \[BID\]) with or without ribavirin (RBV; dosed divided twice a day) for 12 or 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing elective first time CABG~* Patients with at least 1 vessel coronary artery disease undergoing on- pump CABG~Exclusion Criteria:~* Age ≤ 20 years or ≥ 85 years~* Ejection fraction \< 30%~* Unstable angina~* Recent myocardial infarction (\< 1 month)~* Any additional cardiac disease (e.g. arrythmia, aneurysm, valvular/septal disease, dissection or elevated pulmonary artery pressure)~* Any end stage organ failure (e.g. renal and respiratory failure)~* History of chronic obstructive pulmonary disease (COPD)~* Pneumothorax~* Pulmonary bullae~* Convulsions~* Current history of malignancy~* Severe myopia or intraocular lens~* Patients on K+(ATP) Channel Openers e.g. Nicorandil, Oral Hypoglycemics, Opioid Analgesics, Catecholamines.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: NO_INTERVENTION): Patients in this arm were not treated with HBO prior to CABG
- B (Type: EXPERIMENTAL): Patients in this arm were treated with HBO prior to CABG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete